Literature DB >> 34877610

FAP-targeted radionuclide therapy with [177Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma.

Kaili Fu1,2,3, Yizhen Pang2, Liang Zhao3, Limei Lin3, Hua Wu2, Long Sun2, Qin Lin4, Haojun Chen5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34877610     DOI： 10.1007/s00259-021-05634-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  FAP: the next billion dollar nuclear theranostics target ?

Authors:  Jeremie Calais
Journal:  J Nucl Med       Date:  2020-01-10       Impact factor: 10.057

2.  Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study.

Authors:  Majid Assadi; Seyed Javad Rekabpour; Esmail Jafari; GhasemAli Divband; Babak Nikkholgh; Hamidreza Amini; Hassan Kamali; Sakineh Ebrahimi; Nader Shakibazad; Narges Jokar; Iraj Nabipour; Hojjat Ahmadzadehfar
Journal:  Clin Nucl Med       Date:  2021-07-14       Impact factor: 7.794

3.  A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy.

Authors:  Sanjana Ballal; Madhav Prasad Yadav; Vasko Kramer; Euy Sung Moon; Frank Roesch; Madhav Tripathi; Soumyaranjan Mallick; Sreedharan Thankarajan ArunRaj; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-11       Impact factor: 9.236

Review 4.  Turning foes to friends: targeting cancer-associated fibroblasts.

Authors:  Xueman Chen; Erwei Song
Journal:  Nat Rev Drug Discov       Date:  2019-02       Impact factor: 84.694

5.  PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.

Authors:  Justin Ferdinandus; Wolfgang P Fendler; Andrea Farolfi; Samuel Washington; Osama Mohamad; Miguel H Pampaloni; Peter J H Scott; Melissa Rodnick; Benjamin L Viglianti; Matthias Eiber; Ken Herrmann; Johannes Czernin; Wesley R Armstrong; Jeremie Calais; Thomas A Hope; Morand Piert
Journal:  J Nucl Med       Date:  2021-10-07       Impact factor: 11.082
  5 in total
  2 in total

Review 1.  Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer.

Authors:  Ziqi Li; Mariam S Aboian; Xiaohua Zhu; Bernadette Marquez-Nostra
Journal:  Cancers (Basel)       Date:  2022-04-23       Impact factor: 6.575

2.  Radiosynthesis and First Preclinical Evaluation of the Novel 11C-Labeled FAP Inhibitor 11C-FAPI: A Comparative Study of 11C-FAPIs and (68Ga) Ga-DOTA-FAPI-04 in a High-FAP-Expression Mouse Model.

Authors:  Cheng Wang; Zhoumi Hu; Fan Ding; Haitao Zhao; Fuqiang Du; Chun Lv; Lianghua Li; Gang Huang; Jianjun Liu
Journal:  Front Chem       Date:  2022-08-05       Impact factor: 5.545
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.